MedPath

Usefulness of the CADISS® System for the Cleavage of Severe Adhesions in Cholecystectomy

Not Applicable
Completed
Conditions
Cholecystitis, Acute
Interventions
Combination Product: CADISS® System
Registration Number
NCT05041686
Lead Sponsor
AuXin Surgery SA
Brief Summary

Acute cholecystitis is the most common complication of cholelithiasis. Acute cholecystitis is inflammation of the gallbladder that develops over hours, usually due to an obstruction of the cystic duct by a gallstone. Removal of the gallbladder (Cholecystectomy) is the only definitive treatment for acute cholecystitis, with laparoscopic cholecystectomy (LC) considered the gold standard. Serious complications that may occur with laparoscopic cholecystectomy, including bile duct injury, bile leaks, bleeding, and bowel injury, result in part from the anatomy, disease related pathology and structural misidentification due to inflammatory process (Gupta 2019).

The CADISS® System, Chemically Assisted mechanical DISSection, is intended for the selective detachment of pathological tissue layers and/or fibrotic tissues in various surgical procedures without using cutting instruments. It is based on the property of the drug mesna (Sodium 2-mercaptoethane sulfonate) to cleave the disulfide bonds responsible for the adherence of pathological tissues and for the strength of fibrosis. This study is a prospective, multi-sites, open label, single cohort clinical trial evaluating the use of CADISS® system to facilitate dissection of severe adhesions in cholecystectomy and to allow better identification of different structure.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
15
Inclusion Criteria
  • ≥ 18 years old
  • Weight > 30 kg
  • Confirmed diagnosis of acute gallstone cholecystitis
  • Symptomatic or asymptomatic cholecystitis
  • Under surgery for cholecystectomy:
  • for the 5 first patients : cholecystectomy will take place within 72 hours of the first symptoms of cholecystitis
  • after the 5 first patients : cholecystectomy will be allowed at any time after the first symptoms and at physician judgment
  • Patient agrees to signed the informed consent
Exclusion Criteria
  • < 18 years old
  • ≤ 30 kg
  • Known hypersensibility to mesna
  • Patient taking anticoagulant at the screening visit
  • Patient having a pancreatitis or angiocholitis
  • Patients suffering from hepatic or renal disorders
  • Unable to sign the informed consent
  • Participation in any study involving an investigational drug or device within the past 3 Months.
  • Patient is pregnant, breastfeeding or has wish of pregnancy during the study.
  • Individuals under tutorship or trusteeship

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
CADISS® SystemCADISS® System-
Primary Outcome Measures
NameTimeMethod
Ability of the CADISS® System to dissect adherences without cuttingSurgery

Percentage of successful dissection

Secondary Outcome Measures
NameTimeMethod
Adverse eventsSurgery, 2 to 5 days after surgery (Hospital discharge), 6 weeks follow-up

All CADISS® related adverse events will be reported

The change of bleeding with the use of the CADISS SystemSurgery

Likert scale - 0 to 10, the parameter is evaluated in comparison to the current surgeon practice. A score of 5 representing an appreciation of equivalence for the parameter with the current practice. A score above 5 means the use of CADISS System reduction reduce bleeding compared to the current practice.

A change of surgical complication riskSurgery

Likert scale - 0 to 10, the parameter is evaluated in comparison to the current surgeon practice. A score of 5 representing an appreciation of equivalence for the parameter with the current practice. A score above 5 means the use of the CADISS System reduce the risk of surgical complication risks compared to the current practice.

The capability of the CADISS System to highlight the cleavage planeSurgery

Likert scale - 0 to 10, the parameter is evaluated in comparison to the current surgeon practice. A score of 5 representing an appreciation of equivalence for the parameter with the current practice. A score above 5 means an improvement compared to the current practice

The facilitation of detachment with the CADISS SystemSurgery

Likert scale - 0 to 10, the parameter is evaluated in comparison to the current surgeon practice. A score of 5 representing an appreciation of equivalence for the parameter with the current practice

The ease of use of the CADISS SystemSurgery

Likert scale - 0 to 10, A score of 0 representing the worse outcome

The easiness of control of the topical application with the CADISS SystemSurgery

Likert scale - 0 to 10, A score of 0 representing the worse outcome

Trial Locations

Locations (1)

AuXin Surgery

🇧🇪

Louvain-la-Neuve, Belgium

© Copyright 2025. All Rights Reserved by MedPath